P 013
Alternative Names: P-013Latest Information Update: 09 Mar 2023
At a glance
- Originator NB Health Laboratory
- Class Analgesics; Antifibrotics; Monoclonal antibodies
- Mechanism of Action G protein-coupled receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Fibrosis; Pain
Most Recent Events
- 19 Jan 2023 P 013 is available for licensing as of 19 Jan 2023. https://nbhl.co.jp/nbhlhpwordpress/partnering/co-development.html
- 19 Jan 2023 Early research in Fibrosis in Japan (Parenteral) (NB Health Laboratory, January 2023)
- 19 Jan 2023 Early research in Pain in Japan (Parenteral) (NB Health Laboratory, January 2023)